

WOCKHARDT LIMITED
AUDITED CONSOLIDATED FINANCIAL RESULTS
FOR THE YEAR ENDED 31ST DECEMBER, 2008



(Rs. In Million)

PARTICULARS	QUARTER ENDED 31/12/2008	% TO SALES	QUARTER ENDED 31/12/2007	% TO SALES	GROWTH %	YEAR ENDED 31/12/2008	% TO SALES	YEAR ENDED 31/12/2007	% TO SALES	GROWTH %
Net Income from operations	9,519		7,620			35,926		26,532		
Total Expenditure	7,555	77.3	5,719	75.9	32.1	27,844	77.5	20,141	79.7	38.2
a) (Increase)/Decrease in stock	245		(708)			242		(1,492)		
b) Consumption of raw material	2,279		2,314			7,273		7,434		
c) Purchase of Finished Goods	1,460		931			5,847		3,985		
Material Consumption	3,984	40.8	2,537	33.7	57.0	13,362	37.2	9,927	39.3	34.6
d) Staff Cost	1,295		1,449			6,074		4,434		
e) R & D expenditure	13		88			513		505		
f) Other expenditure	2,263		1,645			7,895		5,275		
Other Expenditure	3,571	36.5	3,182	42.2	12.2	14,482	40.3	10,214	40.4	41.8
Gross Profit before Interest, Depreciation & Taxation	1,964	20.6	1,901	24.9	3.3	8,082	22.5	6,391	24.1	26.5
Interest/ Financing Cost										
(a) Interest	907		500		81.4	2,704		1,638		65.1
(b) Income/(Expense) due to Exchange Rate Fluctuation on Foreign Currency Borrowings	812		(29)			(9)		314		
(c) Premium on FCCB	1,295		-			1,295		-		
Gross Profit/(Loss) after Interest but before Depreciation & Taxation	574	6.0	1,372	18.0	(58.2)	4,074	11.3	5,067	19.1	(19.6)
Depreciation	368	3.9	236	3.1	55.9	1,130	3.1	785	3.0	43.9
Profit/(Loss) after Interest & depreciation	206	2.2	1,136	14.9		2,944	8.2	4,282	16.1	
Other Income	131	-	74	-	-	356	-	460	-	-
Exceptional Item Profit/(Loss)	(5,545)		0			(5,810)		0		
Profit/(Loss) before Tax	(5,208)	(54.7)	1,210	15.9		(2,510)	(7.0)	4,742	17.9	
Provision for Taxation	(171)		30			237		527		
Fringe Benefit Tax	9		10			39		36		
Deferred Taxation	(1,331)		115			(1,192)		354		
Profit/(Loss) After Tax	(3,715)		1,055			(1,594)		3,825		
Add: Share of Profit/ (Loss) from Associates	137		33			205		33		
Net Profit/(Loss)	(3,578)	(37.6)	1,088	14.3		(1,389)	(3.9)	3,858	14.5	

PARTICULARS	QUARTER ENDED 31/12/2008	% TO SALES	QUARTER ENDED 31/12/2007	% TO SALES	GROWTH %	YEAR ENDED 31/12/2008	% TO SALES	YEAR ENDED 31/12/2007	% TO SALES	GROWTH %
Paid-up Equity Share Capital (Rs 5/-each)	547		547		-	547		547		-
Reserves excluding Revaluation Reserve (as per last audited Balance-Sheet)	-		-		-	9,630		12,188		-
Earning Per Share										
Basic Earning Per Share (Rs)	(32.69)		9.94			(12.69)		35.25		
Diluted Earning Per Share (Rs)	(32.69)		9.94			(12.69)		35.25		
Public Shareholding										
- Number of Shares	28,102,803		28,075,803			28,102,803		28,075,803		
- Percentage to Paid-up Capital	25.68%		25.66%			25.68%		25.66%		
Promoters and promoter group shareholding										
a) Pledged/ Encumbered										
- Number of shares	69,280,667					69,280,667				
-Percentage of shares (as a % of the total shareholding of promoter and promoter group)	85.97%					85.97%				
-Percentage of shares (as a % of the total share capital of the Company)	63.31%					63.31%				
b) Non-encumbered										
- Number of shares	11,304,715					11,304,715				
-Percentage of shares (as a % of the total shareholding of promoter and promoter group)	14.03%					14.03%				
-Percentage of shares (as a % of the total share capital of the Company)	10.33%					10.33%				

Notes to Financial Results for year ended December 31, 2008:-

- 1) The above results were reviewed by the Audit Committee and approved by the Board of Directors at their meetings held on April 24, 2009
- 2) Pursuant to the announcement on 'Accounting for Derivatives' issued by the Institute of Chartered Accountants of India in March 2008, the Company has accounted Mark-to-Market (MTM) losses aggregating Rs. 4,587 million for the year ended December 31, 2008. The same has been treated as Exceptional Item. The Company has entered into Hedging Instruments, which are long term in nature to reduce interest cost/ Currency risk for the loans, which the Company has taken in past and is outstanding as of December 31, 2008. As per the Risk Mangement Policy, the Company is hedging the interest/ currency risk for the long term loans. The Company does not hold or issue derivative financial instruments for trading or speculative purposes. The Exceptional Item also includes derivative losses of Rs. 1,223 million
- 3) In the month of October 2004, the Company had issued 110,000 Zero Coupon foreign currency convertible bonds of USD 1,000 each. The Bonds are considered as monetary liability. The Bonds are redeemable on maturity date at 129.578 percent of its principal amount, only if there is no conversion of bonds on or before September 25, 2009. The Company is evaluating various options for restructuring the debts of the Company. The FCCB including the premium payable will be part of the restructuring exercise. The Company is proposing to negotiate with the FCCB holders towards discount and/or extension of the due date of payment. During the year the Company has provided for FCCB premium of Rs. 1,295 Million for the period October 2004 to December 2008
- 4) As per note 6 to the Auditors Report for the year ended December 31, 2008, the Company had, on certain derivative contracts with banks, stopped payment of margins called by the banks during the year. Subsequent to the balance sheet date the banks, based on the Early Termination clause in the agreement, terminated these contracts and claimed an amount of Rs 48,952 lakhs, being the loss incurred on termination of such contracts. The Company contends that the forex transactions were unilaterally cancelled by the banks and the mark to market losses had arisen on account of counter positions advised by the banks. The Company has obtained a legal opinion that these contracts can be disputed. No provision has been made in the accounts for these demands which have been disclosed under contingent liabilities. The Company has not determined the quantum of mark to market losses as of the balance sheet date on the above contracts. Pending final settlement of the matter, we are unable to quantify the extent of provision that may be required to be made in this regard.

The Board is of the view the forex transactions were unilaterally cancelled by the banks and the mark to market losses had arisen on account of counter positions advised by the banks. The Company has obtained a legal opinion that these contracts can be disputed, and accordingly no provision for the same has been made. As the contracts are disputed it is not possible to ascertain the quantum of liability and accordingly the impact of the same on the profit or loss of the Company
- 5) As on October 1, 2008 the Company had no investors complaints pending. During the quarter the Company has received not received any complaints. Accordingly, no complaints are pending as on December 31, 2008
- 6) The Company is exclusively into Pharmaceutical business Segment.
- 7) Previous period figures have been recast/ re-classified to conform to the current period's presentation.
- 8) Standalone Financials of the Company are available on the websites of National Stock Exchange and Bombay Stock Exchange